Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas
Stopped Modified dose schedule presented no advantage over previously studied schedule
Conditions
- Advanced Solid Tumors
- Lymphoma
Interventions
Sponsor
Cylene Pharmaceuticals